The Enterprise Value as of December 2024 (TTM) for Cellectis S.A. (CLLS) is 43.67M

According to Cellectis S.A.’s latest financial reports and current stock price. The company's current Enterprise Value is 43.67M. This represents a change of -67.84% compared to the average of 135.77M of the last 4 quarters.

Cellectis S.A. (CLLS) Historical Enterprise Value (quarterly & annually)

How has CLLS Enterprise Value performed in the past?

The mean historical Enterprise Value of Cellectis S.A. over the last ten years is 429.66M. The current 43.67M Enterprise Value has changed 916.34% with respect to the historical average. Over the past ten years (40 quarters), CLLS's Enterprise Value was at its highest in in the December 2020 quarter at 1.11B. The Enterprise Value was at its lowest in in the December 2022 quarter at 81.72M.

Cellectis S.A. (CLLS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Cellectis S.A. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cellectis S.A. (CLLS) Average Enterprise Value

How has CLLS Enterprise Value performed in the past?

The current Enterprise Value of Cellectis S.A. (CLLS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Cellectis S.A. (CLLS) Enterprise Value vs. Peers

How is CLLS’s Enterprise Value compared to its peers?

Cellectis S.A.’s Enterprise Value is greater than Sigilon Therapeutics, Inc. (42.21M), less than DiaMedica Therapeutics Inc. (221.15M), greater than NeuBase Therapeutics, Inc. (-5817093.00), less than Soleno Therapeutics, Inc. (1.88B), less than Genfit S.A. (179.69M), greater than Cyteir Therapeutics, Inc. (-20511738.00), greater than ERYTECH Pharma S.A. (26.49M), less than Eliem Therapeutics, Inc. (0), greater than HCW Biologics Inc. (26.86M), less than Innate Pharma S.A. (124.46M), greater than Inhibrx Biosciences, Inc. (15.26M), greater than Anebulo Pharmaceuticals, Inc. (40.61M), less than Crinetics Pharmaceuticals, Inc. (4.74B), greater than Passage Bio, Inc. (33.76M), less than REGENXBIO Inc. (394.08M), greater than LianBio (-66141903.00), greater than Kezar Life Sciences, Inc. (29.92M), less than Foghorn Therapeutics Inc. (260.47M), greater than Shattuck Labs, Inc. (12.78M), less than Monte Rosa Therapeutics, Inc. (351.25M), less than Kymera Therapeutics, Inc. (2.62B), less than Nurix Therapeutics, Inc. (1.31B),

Build a custom stock screener for Cellectis S.A. (CLLS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cellectis S.A. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cellectis S.A. (CLLS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cellectis S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.